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Abstract
Background: The peroxisome proliferator-activated receptor (PPAR)-a activator, 5,8,11,14-eicosatetraynoic acid (ETYA),
is an arachidonic acid analog. It is reported to inhibit up-regulation of pro-inflammatory genes; however, its underlying
mechanism of action is largely unknown. In the present study, we focused on the inhibitory action of ETYA on the
expression of the chemokine, CCL2/MCP-1, which plays a key role in the initiation and progression of inflammation.
Methods: To determine the effect of ETYA, primary cultured rat astrocytes and microglia were stimulated with IFN-
g in the presence of ETYA and then, expression of CCL2/MCP-1 and MAPK phosphatase (MKP-1) were determined
using RT-PCR and ELISA. MKP-1 mRNA stability was evaluated by treating actinomycin D. The effect of MKP-1 and
human antigen R (HuR) was analyzed by using specific siRNA transfection system. The localization of HuR was
analyzed by immunocytochemistry and subcellular fractionation experiment.
Results: We found that ETYA suppressed CCL2/MCP-1 transcription and secretion of CCL2/MCP-1 protein through up-
regulation of MKP-1mRNA levels, resulting in suppression of c-Jun N-terminal kinase (JNK) phosphorylation and activator
protein 1 (AP1) activity in IFN-g-stimulated brain glial cells. Moreover, these effects of ETYA were independent of PPAR-
a. Experiments using actinomycin D revealed that the ETYA-induced increase in MKP-1 mRNA levels reflected an
increase in transcript stability. Knockdown experiments using small interfering RNA demonstrated that this increase in
MKP-1 mRNA stability depended on HuR, an RNA-binding protein known to promote enhanced mRNA stability.
Furthermore, ETYA-induced, HuR-mediated mRNA stabilization resulted from HuR-MKP-1 nucleocytoplasmic
translocation, which served to protect MKP-1 mRNA from the mRNA degradation machinery.
Conclusion: ETYA induces MKP-1 through HuR at the post-transcriptional level in a receptor-independent manner.
The mechanism revealed here suggests eicosanoids as potential therapeutic modulators of inflammation that act
through a novel target.
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Introduction
Inflammatory responses in the brain contribute to the
pathogenesis of neurodegenerative disease, such as Alz-
heimer’s disease, multiple sclerosis, and brain ischemia
[1-4]. These responses are characterized by a sequential
process involving the release of pro-inflammatory
cytokines, increased expression of endothelial adhesion
molecules and chemotactic factors, and activation of
brain immune effector cells [5,6].
Microglia and astrocytes are representative immune
cells in the brain. When microglia and astrocytes
become activated by a variety of stimuli, they produce
inflammatory cytokines and chemokines, which acceler-
ate disease progression [7-11]. Among the inflammatory
chemokines elaborated, glial cell-derived CCL2/MCP-1
is crucial: by promoting the migration and recruitment
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any medium, provided the original work is properly cited.of inflammatory cells, it is primarily responsible for the
initiation and progression of inflammatory responses
[12]. In an animal model of prion disease, mice deficient
in CCL2/MCP-1 showed a delayed onset of inflamma-
tory disease and an increase in survival time [13].
CCL2/MCP-1 overexpression is also associated with a
variety of disease states, including atherosclerosis [14,15]
and ischemic stroke [16]. Therefore, intervention aimed
at suppressing CCL2/MCP-1 expression is an emerging
therapeutic strategy for the treatment of neurodegenera-
tive diseases.
As a part of this therapeutic approach, peroxisome
proliferator-activated receptors (PPARs) have received
recent research attention. PPARs, which comprise three
members–a, g and b/δ–are ligand-activated transcrip-
tion factors that form a subfamily of the nuclear recep-
tor gene family. PPARs were originally reported to be
highly expressed in adipocytes and were shown to play
important roles in adipocyte differentiation, lipid bio-
synthesis, and glucose homeostasis [17,18]. However,
subsequent studies have suggested that each PPAR sub-
type has anti-inflammatory effects in various cell types
[19,20]. One of them, PPAR-a, exerts its anti-inflamma-
tory functions by negatively regulating the expression of
pro-inflammatory molecules [21-23]. In the brain,
PPAR-a activators have been shown to inhibit the pro-
duction of nitric oxide and the secretion of pro-inflam-
matory cytokines, including TNF-a,I L - 1 b,a n dI L - 6i n
glial cells [24-26]. Thus, PPAR-a activators have shown
promising beneficial effects in several animal models of
CNS disorders in which an inflammatory component is
strongly implicated, such as multiple sclerosis, Parkin-
son’s disease, Alzheimer’s disease, and ischemic brain
injury [27-29].
Although significant advances have been made in our
understanding of the molecular mechanisms of PPAR-a
activators during metabolic processes, much less is
known about the anti-inflammatory mechanisms of
PPAR-a activators during inflammation. For example,
accumulating evidence suggests that PPAR activators act
in a receptor-independent manner in various cell types.
In one such case, the PPAR-g activator, 15-deoxy-
Δ12,14-prostaglandin J2 (15d-PGJ2), was shown to sup-
press inflammatory cytokines in a receptor-independent
manner [30-32]. Activators of PPAR-a have also proven
effective against experimental autoimmune encephalo-
myelitis (EAE) independent of PPAR-a [33]. Thus,
PPAR activators are multifaceted modulators of inflam-
matory responses, functioning through both receptor-
dependent and -independent mechanisms.
Here, we evaluated the anti-inflammatory effects of
three fibrates, WY14643, fenofibrate, clofibrate, and the
eicosanoid, 5,8,11,14-eicosatetraynoic acid (ETYA), as
PPAR-a activators. Our results showed that ETYA, but
not fibrates, acted through a PPAR-a-independent
mechanism to suppress JNK-mediated CCL2/MCP-1
expression by inducing MKP-1 (MAPK phosphatase), a
negative regulator of MAPK. ETYA-induced MKP-1
expression resulted from a HuR-mediated increase in
MKP-1 mRNA stability. These findings suggest an addi-
tional therapeutic use of known anti-inflammatory
agents based on a novel mechanism targeting post-tran-
scriptional regulation.
Materials and methods
Reagents
IFN-g was purchased from Calbiochem (Butler Pike,
PA). Antibodies against phospho-JNK, phospho-MKP-1
and histone deacetylase (HDAC)1 were purchased from
Cell Signaling (Beverly, MA). Anti-MKP-1, anti-HuR,
anti-decaping protein (DCP)1a, anti-T cell internal anti-
gen (TIA)1, anti-TIA1 related (TIAR), Lamin B,
GAPDH and methyl CpG binding domain (MBD)3 anti-
bodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). ETYA, WY-14643, clofibrate, and 2-
arachidonylglycerol (2-AG) were purchased from BIO-
MOL (Plymouth Meeting, PA). Fenofibrate and actino-
mycin D (Act D) were purchased from Sigma (St. Louis,
MO).
Cell culture
Primary microglia and astrocytes were cultured from the
cerebral cortices of 1-day-old Sprague-Dawley rats. Cor-
tices were triturated into single cells in minimal essen-
tial media (MEM) containing 10% fetal bovine serum
( H y c l o n e ,L o g a n ,U T ) ,p l a t e do n t o7 5 - c m
2T-flasks, and
cultured for 2 weeks. Following the removal of micro-
glia, primary astrocytes were isolated by trypsinization.
Microglia and meningeal cells were depleted by incubat-
ing astrocytes in serum-free MEM for 2 days before use.
Final cultures were shown to consist of more than 95%
authentic astrocytes by glial fibrillary acidic protein
(GFAP) staining.
Reverse transcription-polymerase chain reaction (RT-PCR)
and quantitative RT-PCR analysis
Total RNA was isolated using TRIzol (Invitrogen, Carls-
bad, CA), and cDNA was prepared using Avian Myelo-
blastosis Virus reverse transcriptase (GenDEPOT,
Barker, TX), according to the manufacturers’ instruc-
tions. Conventional PCR was performed using 32 cycles
of sequential reactions. The following primer pairs for
the indicated targets were purchased from Bioneer (Dae-
j e o n ,K o r e a ) :G A P D H ,5 ’-TCC CTC AAG ATT GTC
AGC AA-3’ (forward) and 5’-AGA TCC ACA ACG
GAT ACA TT-3’ (reverse); TNF-a,5 ’-GTA GCC CAC
GTC GTA GCA AA-3’ (forward) and 5’-CCC TTC
TCC AGC TGG GAG AC-3’ (reverse); CCL2/MCP-1,
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and 5’-CTA GTT CTC TGT CAT ACT GG-3’ (reverse);
MKP-1, 5’-AGG ACA CCA CAA GGC AGA C-3’ (for-
ward) and 5’-TGA TGG GGC TTT GAA GGT AG-3’
(reverse); PPAR-a,5 ’-TTC GGA AAC TGC AGA CCT-
3’ (forward) and 5’-TTA GGA ACT CTC GGG TGA T-
3’ (reverse); cannabinoid receptor (CB)1, 5’-TCC CAG
GGA GAG GAG AGT GT-3’ (forward) and 5’-GCC
GTC ACC AGG TTT TCA CT-3’ (reverse). For quanti-
tative PCR, the amplification reactions were performed
with KAPA SYBR qPCR master mix (KAPA Biosystems,
Woburn, MA) according to the manufacturer’s specifica-
tions. Amplification conditions were as follows: 40
cycles of 3 s at 95°C, 15 s at 55°C, and 15 s at 72 C.
After amplification was complete, a melting curve was
generated by heating at 1°C per second to 95°C. Melting
curves were generated and data were quantitatively ana-
lyzed using Rotor Gene Q, version 1.7. The sequences
of primers for quantitative RT-PCR were as follows:
CCL2/MCP-1, 5’-ATG CAG TTA ATG CCC CAC TC-
3’ (forward) and 5’-TTC CTT ATT GGG GTC AGC
AC-3’ (reverse); MKP-1, 5’-TAG ACT CCA TCA AGG
ATG CTG G-3’ (forward) and 5’-GCA GCT CGG AGA
GGT TGT GAT-3’ (reverse); GAPDH, 5’-GGC CAA
AAG GGT CAT CAT C-3’ (forward) and 5’-GTG ATG
CCA TGG ACT GTG G-3’ (reverse).
Western blot analysis
Cell lysates for Western blot analysis, prepared as pre-
viously described [32], were separated by SDS-PAGE
and transferred to nitrocellulose membranes. Mem-
branes were incubated with primary antibodies and
HRP-conjugated secondary antibodies, and bands were
visualized using an enhanced chemiluminescence system
(Ab Frontier, Korea).
EMSA
EMSAs were conducted following a previously reported
method [32]. The oligonucleotide probe, 5’-CCT GAC
TCC ACC TCT GGC-3’,s p e c i f i cf o rt h eA P 1b i n d i n g
site of the rat CCL2/MCP-1 promoter (positions -129 to
-111) was purchased from Bioneer. For supershift
experiments, protein extracts were incubated with 0.2
μg of anti-c-Jun antibody (Santa Cruz Biotechnology)
for 1 h prior to the addition of g-
32P-labeled probe.
ELISA
Primary microglia and astrocytes were seeded onto 6-
well plates. After incubating cells with IFN-g in the pre-
sence or absence of ETYA or fibrates, 500 μl of cell-
conditioned media was collected and assayed using rat
CCL2/MCP-1 ELISA kits (BD Biosciences, San Diego,
CA), according to the manufacturer’s instructions.
Construction of luciferase reporter plasmids and
luciferase assay
Rat CCL2/MCP-1 promoter fragments corresponding to
positions -3554 to +76 (pGL3-CCL2/MCP-1), -2355 to
-81 (pGL3-B-AP1-SP1), -2404 to -2062 (pGL3-B) and
-228 to +45 (pGL3-AP1-Sp-1) were amplified by PCR
using rat genomic DNA as a template and specific pri-
mer sets. Transient transfections were performed using
Lipofectamine 2000 reagents (Invitrogen) as described
by the manufacturer. After incubating transfected cells
for 48 h, luciferase activity was measured using a lumin-
ometer (PerkinElmer Vitor
3) and normalized to b-galac-
tosidase activity (measured at A420)
ChIP assay
ChIP assays were performed as described previously
[32]. Cell supernatants were immunoprecipitated with
anti-c-Jun antibodies overnight at 4°C; protein-bound,
immunoprecipitated DNA was recovered by phenol/
chloroform extraction and then amplified by PCR using
the primer pair, 5’-TTC CAC TCT CCA TCG CTC
AT- 3’ (forward) and 5’-TCT GCA TTT CTA GCG
GCT CT-3’ (reverse), spanning the promoter region of
CCL2/MCP-1 (position -155 to -71) containing AP1
elements.
Immunostaining and confocal microscopy
Astrocytes cultured on poly-D-lysine-coated coverslips
were fixed with methanol at -20°C for 30 min. Fixed
cells were incubated with anti-HuR and anti-GFAP
(Sigma) antibodies at 4°C overnight, and then with
fluorescein- or rhodamine-conjugated secondary antibo-
dies (Molecular Probes, Eugene, OR) for 2 h. Coverslips
were slide-mounted and observed under a confocal
microscope (Zeiss, Germany).
Synthesis and transfection of small interfering RNA
siRNA duplex oligonucleotides targeting MKP-1 (5’-
CCA ATT GTC CTA ACC ACT T-3’), CB1 (5’-CGA
AGG UGA CCA UGU CUG UTT-3’), HuR (5’-GAU
GCC AAC UUG UAC AUC ATT-3’)a n dP P A R - a (5’-
GGC UAA AGC UGG CGU ACG AUU-3’) were chemi-
cally synthesized by Bioneer (Korea). Confluent astro-
cytes and microglia were transfected with siRNA
oligonucleotides using Lipofectamine RNAiMAX (Invi-
trogen), according to the manufacturer’si n s t r u c t i o n s .
All assays were performed at least 48 h after siRNA
transfection.
Phosphatase assay
Cell extracts were prepared by immunoprecipitation, as
previously described [32]. Briefly, lysates (300 μg) were
incubated with an anti-MKP-1 antibody (1 μg) at 4°C
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G-agarose beads (Upstate Biotechnology) for 2 h at 4°C.
Phosphatase activity was measured in two ways. In the
first, MKP-1 activity was measured by incubating immu-
noprecipitated proteins with the substrate, p-nitrophe-
nylphosphate (p-NPP) (Sigma), for 4 h at 37°C followed
by spectrophotometric analysis at 405 nm. In the sec-
ond, specific p-JNK-linked MKP-1 activity was measured
by incubating immunoprecipitated proteins with lysates
from IFN-g-stimulated astrocytes (as substrates). Bead-
protein conjugates and lysates were then boiled, and the
resulting eluates were analyzed by Western blotting
using antibodies against MKP-1 or phospho-JNK.
Statistical analysis
Differences among groups were determined using one-
way ANOVA. A p-value of 0.05 was considered statisti-
cally significant. Values are presented as means ± SEMs
or ± SDs
Results
ETYA suppresses CCL2/MCP-1 transcription and protein
secretion by inhibiting AP1 signaling in IFN-g-activated
brain astrocytes
First, we screened the anti-inflammatory profiles of
PPAR-a activators in IFN-g-stimulated brain astrocytes
using RT-PCR analyses and ELISAs. Astrocytes were sti-
mulated with IFN-g (10 U/ml) in the absence or pre-
sence of one of four PPAR-a activators: the three
fibrates, WY14643, clofibrate and fenofibrate; and the
eicosanoid, ETYA. Effective concentration of individual
agent was determined according to a dose test result
(Additional file 1: Figure S1). TNF-a and CCL2/MCP-1
transcript levels and protein released into media were
measured 3 and 12 h after IFN-g treatment, respectively.
TNF-a transcript and released protein levels were sup-
pressed by all PPAR-a activators, whereas those of
CCL2/MCP-1 were inhibited by ETYA, but not by
fibrates (Figure 1A and 1B).
B e c a u s ew eh a v ep r e v i o u s l ys h o w nt h a tC C L 2 / M C P - 1
expression is critically regulated by JNK/AP1 signaling
in brain astrocytes [32], we examined whether ETYA
acted through inhibition of JNK/AP1 to suppress CCL2/
MCP-1 expression. Using variably deleted rat CCL2/
MCP-1 promoter/luciferase reporter gene constructs
(refer to Materials and Methods), we tested whether
fibrates and ETYA affected CCL2/MCP-1 transcription.
IFN-g-induced increases in the luciferase activity of pro-
moters containing AP1/SP1 sites were suppressed by
ETYA, but not by WY14643 (Figure 2A). To further
evaluate the effect of ETYA, we performed EMSAs and
ChIP assays. These assays confirmed that ETYA, but not
fibrates, effectively inhibited c-Jun binding to the pro-
moter of the CCL2/MCP-1 gene (Figure 2B and 2C).
AP1 is composed of JNK-phosphorylated c-Jun homodi-
mers or heterodimers with c-Fos [34]. Thus, we exam-
ined whether ETYA acted at the level of JNK
phosphorylation. JNK phosphorylation, which was evi-
dent within 2 h of IFN-g stimulation, was markedly sup-
pressed by ETYA, but not by WY14643 (Figure 2D). To
confirm the functional relevance of pJNK suppression
by ETYA, we checked whether ETYA affected the locali-
zation of MBD3 and HDAC1, which were known to
repress target gene expression by binding to AP-1 site
of target gene in a JNK phosphorylation-dependent
manner [35]. Using ChIP assay, we observed that bind-
i n go fM B D 3a n dH D A C 1t ot h eM C P - 1p r o m o t e ri s
increased in ETYA-treated group as compared to IFN-g-
treated group. These results confirm that ETYA-
mediated JNK inactivation functionally affect MCP-1
gene expression (Additional file 2: Figure S2). Collec-
tively, these results indicate that ETYA, but not fibrates,
effectively suppressed CCL2/MCP-1 expression in IFN-
g-stimulated astrocytes by inhibiting AP1 signaling.
The suppressive actions of ETYA on JNK/AP1 are
mediated by MKP-1 and are independent of PPAR-a
We have previously reported that MKP-1, which is a
negative regulator of JNK, is critically involved in CCL2/
MCP-1 expression [32]. On the basis of these observa-
tions, we examined whether the regulation of JNK
B 
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Figure 1 ETYA, but not fibrates, reduces CCL2/MCP-1 transcript
levels and protein release in IFN-g-stimulated astrocytes. (A
and B) Primary astrocytes were stimulated with IFN-g for 3 h (A)o r
12 h (B) in the presence of the indicated levels of individual PPAR-a
activators. Then, CCL2/MCP-1 and TNF-a mRNA levels and protein
secretion into media were determined using qRT-PCR and ELISA,
respectively. Data are presented as means ± SDs or SEMs of three
independent experiments (*p < 0.01 versus IFN-g group).
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Page 4 of 13phosphorylation and CCL2/MCP-1 expression in IFN-g-
stimulated astrocytes by ETYA was a consequence of
ETYA-induced modulation of MKP-1. qRT-PCR and
Western blot analyses showed that MKP-1 mRNA and
protein, respectively, were induced within 2 h in the
presence of ETYA. The increased level of MKP-1 was
significantly correlated with a decrease in JNK phos-
phorylation and suppression of CCL2/MCP-1 expression
(Figure 3A and 3B). Additionally, MKP-1 phosphatase
activity was markedly increased with ETYA treatment
( F i g u r e3 C ) .T h e s er e s u l t sw e r ec o n f i r m e di nam o r e
specific phosphatase assay using lysates containing
excess phospho-JNK as a MKP-1 substrate instead of
the synthetic substrate, p-NPP (see Materials and Meth-
ods for details) (Figure 3D). Moreover, these effects of
ETYA on CCL2/MCP-1 expression were reversed by
siRNA-mediated MKP-1 knockdown, indicating that
MKP-1 likely mediates these effects (Figure 3E and 3F).
Taken together, these results clearly indicate that ETYA
induces an increase in the expression level and enzy-
matic activity of MKP-1.
Because ETYA is known as a PPAR-a activator [36],
we examined whether the actions of ETYA on MKP-1
are receptor-dependent or independent. As shown in
Figure 3G and 3H, ETYA-induced MKP-1 expression
was not reversed by siRNA-mediated PPAR-a knock-
down; CCL2/MCP-1 expression levels were also unaf-
fected (Figure 3I) suggesting that ETYA acted in a
receptor-independent manner.
CCL2/MCP-1 suppression by ETYA in brain microglia is
also mediated by the induction of MKP-1
Next, we examined whether the differential effects of
fibrates and ETYA on CCL2/MCP-1 and MKP-1 expres-
sion were evident in rat microglia, which are resident
immune effector cells in the CNS. Rat microglia were
stimulated with IFN-g in the absence or presence of
WY14643 or ETYA. Consistent with the results
obtained from astrocytes, ETYA inhibited IFN-g-induced
increases in the levels of CCL2/MCP-1 transcripts and
protein, and simultaneously induced MKP-1 levels (Fig-
ure 4A-C). These effects were reversed by MKP-1
knockdown (Figure 4D and 4E), but not by siRNA-
mediated PPAR-a knockdown (Figure 4F and 4G). In
contrast to the data obtained with glial cells, fibrates
and ETYA induced equivalent suppression of CCL2/
MCP-1 expression in rat peritoneal macrophages (Addi-
tional file 3: Figure S3), suggesting that the differential
effects of fibrates and ETYA are glial-cell specific.
ETYA increases MKP-1 mRNA stability by inducing HuR
cytoplasmic translocation
MKP-1 expression is controlled at multiple levels. Sev-
eral transcription factors, including SP1, SP3 and AP1,
are known to influence MKP-1 expression at the tran-
scriptional level in response to stress stimuli [37,38].
However, relatively little is known about the post-tran-
scriptional regulation of MKP-1, despite the fact that
MKP-1 is an early response gene and, thus, is likely to
be encoded by a short-lived mRNA [39,40]. Because
treatment with ETYA maintained elevated MKP-1
mRNA levels for up to 5 h (data not shown), we
hypothesized that these agents increased MKP-1 mRNA
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Figure 2 ETYA-induced CCL2/MCP-1 suppression depends on
the inhibition of JNK-AP1 signals. (A) Astrocytes were transiently
transfected with the indicated 5’-deleted CCL2/MCP-1 promoter
constructs and incubated for 48 h. After stimulation with IFN-g in
the presence of the indicated activators for 6 h, cells were
harvested and luciferase activity was measured and plotted as fold-
induction over untreated controls. Data are presented as means ±
SEMs for three independent experiments (*p < 0.05 versus IFN-g
group). (B) Astrocytes were stimulated with IFN-g in the presence of
the indicated PPAR-a activators, and nuclear factor binding activities
of AP1 were measured by EMSA using oligonucleotide probes
specific for the AP1 site of the rat CCL2/MCP-1 promoter (-129 to
-111). The arrows represent specific DNA-protein complexes. (C)
Astrocytes were treated with ETYA or WY-14643 and prepared for
ChIP assays (see Materials and Methods for details). “Input” indicates
control PCR and shows the amount of CCL2/MCP-1 promoter DNA
present in each sample before ChIP. (D) After stimulating astrocytes
with IFN-g for 2 h in the presence of ETYA or WY-14643, JNK activity
was measured by Western blot analysis using an anti-phospho-JNK
antibody. The bar graph represents the intensities of pJNK bands
normalized against those of a-tubulin (bottom panel). The data are
presented as means ± SDs of three independent experiments. *p <
0.05, NS; non significant.
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Figure 3 ETYA acts in a PPAR-a-independent manner to suppress CCL2/MCP-1 expression through induction of MKP-1 expression and
phosphatase activity. (A and B) ETYA- or WY-14643-treated astrocytes were stimulated with IFN-g for 2 h. MKP-1 protein levels and JNK
phosphorylation were analyzed by Western blotting (A), and MKP-1 and CCL2/MCP-1 transcript levels were determined by qRT-PCR (B). (C and D)
Cell lysates immunoprecipitated with an anti-MKP-1 antibody were incubated with p-NPP for 4 h and then analyzed spectrophotometrically at 405
nm (C), or incubated with lysates from IFN-g-activated astrocytes followed by Western blot analysis of eluates (D). (E-I) Primary astrocytes were
transfected with an MKP-1-specific (E and F) or PPAR-a-specific siRNA duplex (G-I) or a nonsilencing control siRNA. Forty-eight h after transfection,
cells were stimulated with IFN-g for 2 h or 12 h in the absence or presence of ETYA. MKP-1 protein levels and phospho-JNK, and transcript levels of
MKP-1 and CCL2/MCP-1 were determined by Western blot analysis (E and G) and qRT-PCR (F and H). MCP-1 protein secretion was analyzed by
ELISA (I). Efficiency of siRNA-mediated PPAR-a silencing was demonstrated by monitoring expression of acetyl CoA synthase (ACS), a PPAR-a-
dependent gene (data not shown). Values are means ± SDs. of three independent experiments. *p < 0.05, ** p < 0.01, NS; non significant.
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Figure 4 ETYA suppresses CCL2/MCP-1 expression by inducing MKP-1 expression in brain microglia. (A - C) Primary microglia were
stimulated with 10 U/ml IFN-g for 2 h or 12 h in the presence of ETYA or WY-14643. MKP-1 protein expression and JNK phosphorylation were
analyzed by Western blotting (A), and MKP-1 and CCL2/MCP-1 transcript levels and protein release were examined by qRT-PCR (B) and ELISA (C).
(D - G) Rat microglia were transfected with a siRNA duplex specific for MKP-1 (D and E) or PPAR-a (F and G). After 48 h, cells were stimulated
with IFN-g for 2 h in the presence or absence of ETYA. MKP-1 protein and JNK phosphorylation were analyzed by Western blotting (D and F),
and MKP-1 and CCL2/MCP-1 transcript levels were examined by RT-PCR (E and G). Values are means ± SDs of three independent experiments.
*p < 0.05, **p < 0.01, NS; non significant.
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Page 7 of 13levels through a post-transcriptional mechanism. To
investigate this possibility, we treated astrocytes with the
transcriptional inhibitor, actinomycin D (Act D), in the
absence or presence of ETYA. MKP-1 mRNA levels
were reduced in a time-dependent manner by Act D
treatment. This effect was reversed by ETYA (Figure
5A), which had no effect on MKP-1 mRNA levels.
These results suggest that ETYA regulates MKP-1
mRNA stability at the post-transcriptional level.
MKP-1 mRNA stabilization is mediated by various
RNA binding proteins (RNA-BPs), including NF-90 and
HuR [41]. Previous study showed that HuR influences
MKP-1 stability through binding to MKP-1 AU-rich ele-
ments (AREs) in the 3’-untranslated region (UTR)
[41-43]. We thus inferred that HuR was involved in
ETYA-induced MKP-1 mRNA stabilization mechanism.
To determine this possibility, we tested the effects of
siRNA against HuR on MKP-1 mRNA levels. As shown
in Figure 5B and 5C, siRNA-mediated HuR knockdown
inhibited the stabilizing effect of ETYA on MKP-1
mRNA. Because the influence of HuR on the expression
of target mRNAs is linked to its cytoplasmic export, we
next examined whether ETYA induced HuR cytoplasmic
translocation. The results of subcellular fractionation
experiments showed that ETYA increased the cytoplas-
mic translocation of HuR, but had no effect on other
RNA-BPs (Figure 5D); this effect was also confirmed
using an immunocytochemical approach. Namely, HuR
was shown to retain its nuclear localization in untreated
astrocytes, whereas in cells treated with ETYA, HuR was
partly displaced into the cytoplasm (0.5 h), and over
time, appeared in a spotted fashion in the cytoplasm (2
h) (Figure 5E). Taken together, these results suggest that
ETYA induces MKP-1 mRNA stability by increasing
HuR cytoplasmic translocation.
Discussion
Although anti-inflammatory effects of PPAR-a activators
in various cell types have been reported, the underlying
mechanisms are largely unknown. Different PPAR-a
activators have distinctive effects on inflammation
depending on cell type or stimulus. Accordingly, we
questioned which of these various agents had specific
anti-inflammatory effects in brain glial cell, and sought
to identify the underlying mechanism. In this study, we
demonstrated that ETYA, but not fibrates, act in a
PPAR-a-independent manner to suppress the expression
of CCL2/MCP-1 by increasing HuR-mediated-MKP-1
mRNA stability. This pathway is summarized in Figure
6.
MKP-1, a dual specificity (Ser/Thr or Thr/Tyr) protein
phosphatase, is responsible for the inactivation of JNK/
p38, and therefore controls MAPK-dependent inflamma-
tion during the innate immune response [44]. The roles
of MKP-1 in inflammation are relatively well identified,
and our previous studies also showed that 15d-PGJ2,a
PPAR-g activator, suppressed brain glial cell-mediated
inflammatory responses through regulation of MKP-1
[32]. However, the detailed mechanism by which MKP-1
expression was regulated by PPAR activators remained
to be established. MKP-1 expression could be regulated
at transcriptional or post-transcriptional levels. Although
several transcription factors, including SP1, SP3 and
AP1, are known to be involved in the transcriptional
regulation of MKP-1 in response to growth factors and
stress stimuli [37,38], it is unlikely that ETYA acts
through such a mechanism because it had no effect on
the activity of these transcription factors (data not
shown). Instead, because MKP-1 is an early response
gene with a short-lived mRNA, it is likely to be regu-
lated post-transcriptionally. Our study showed that
ETYA treatment maintained MKP-1 mRNA levels for
up to 5 h after mRNA synthesis was blocked with Act
D, revealing that ETYA acted at the post-transcriptional
level to increase MKP-1 mRNA stability (Figure 5).
The transient, stimulus-driven stabilization of early
response transcripts is controlled by sequence-specific
RNA-BPs that influence mRNA metabolism [45]. RNA-
BPs that inhibit mRNA decay include the embryonic
lethal abnormal vision (Hu/elav) family of RNA-BPs,
consisting of the ubiquitous HuR (HuA) protein and the
p r i m a r i l yn e u r o n a lp r o t e i n s ,H u B( H e l - N 1 ) ,H u C ,a n d
HuD [46]. The most extensively studied member, HuR,
binds to the AREs present in 3’-UTR of target mRNA
and subsequently translocated to the cytoplasm, where
it increases the half-life of many mRNAs, such as
cyclooxygenase-2 (COX-2), inducible nitric oxide
(iNOS), and MKP-1 [41,47,48]. We confirmed that the
ETYA-induced increase in MKP-1 stability is mediated
by HuR and occurs through the cytoplasmic transloca-
tion of HuR. Interestingly, we observed that this cyto-
plasmic HuR tended to form spot-like aggregates over
time (Figure 5). Using a confocal imaging system, we
c o n f i r m e dt h a tt h e s ea g g r e g ates were co-localized with
stress granules (SGs), but not processing bodies (PBs)
(Additional file 4: Figure S4). SGs are transient, dynamic
cytoplasmic sites containing aggregates of mRNA.
Unlike PBs, which contain mRNA decay machinery, SGs
consist of translation initiation factors, small ribosomal
subunits, and a diverse group of mRNAs and proteins,
and are linked to RNA metabolism. Some RNA-BPs,
such as tristetraprolin (TTP) and butyrate response fac-
tor (BRF)1, a subunit of the RNA polymerase III tran-
scription initiation factor IIIB, destabilize specific
transcripts, whereas other stabilizing proteins, such as
HuR, bind transcripts for export or storage until stress
conditions are alleviated [49]. Thus, SGs are thought to
be passive repositories of the untranslated mRNAs that
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Figure 5 The ETYA-induced increase in MKP-1 expression involves a HuR-mediated increase in MKP-1 mRNA stability resulting from
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mRNA levels were determined by conventional RT-PCR (left, upper panel) and qRT-PCR (right panel). The bar graph represents the intensities of
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Page 9 of 13accumulate during stress, and serve to enable reinitia-
tion of translation when environmental conditions
improve. In this study, we speculated that ETYA
induced a process in which cytosol-exported HuR
caused accumulation of MKP-1 mRNA transcripts in
SGs, preventing them from decaying under unfavorable
conditions.
These observations give rise to a question: how does
ETYA induce HuR export to the cytoplasm? Recent
reports have shown that phosphorylation of HuR within
the hinge region is mediated by protein kinase C (PKC;
isoforms a and δ) and cyclin-dependent kinase (Cdk) and
these are linked to the nucleocytoplasmic translocation of
HuR [50-52]. Phosphorylation of HuR at S158 and S221
by PKC has been implicated in the translocation of HuR
to the cytoplasm, whereas Cdk1-mediated phosphorylation
at HuR at S202 helps to maintain HuR in the nucleus.
Thus, the effects of ETYA on MKP-1 could be achieved by
HuR phosphorylation via PKC or Cdk1. To verify this pos-
sibility, we first examined whether ETYA induces HuR
serine phosphorylation. Immunoprecipitation experiments
using nuclear/cytoplasmic extracts revealed that ETYA
induced HuR serine phosphorylation (Additional file 5:
Figure S5). Although it is reasonable to suppose that these
modifications are linked to cytoplasmic translocation, we
did not determine which serine residues of HuR are phos-
phorylated by ETYA. Thus, further studies are needed to
clarify which serine sites are phosphorylated by ETYA and
which upstream molecules (PKC or Cdk) are regulated by
ETYA.
Recently, accumulating evidence suggests that cannabi-
noids act (directly or indirectly) to suppress inflammation-
dependent neurodegeneration via inhibition of pro-inflam-
matory cytokine expression, and that of reactive oxygen
intermediates; several cellular pathways are involved
[53,54]. Of particular interest in this context are recent
reports addressing functional interactions between canna-
binoids and anti-inflammatory nuclear receptors, including
PPARs [55-57]. These studies suggest that a novel
mechanism potentiating anti-inflammatory capacity upon
brain inflammation may be in play. As endocannabinoids
such as anandamide (AEA) and 2-AG are derived from
arachidonic acid synthesized within the body, it is likely
that endocannabinoids and ETYA share structural and
functional similarities [58]. Moreover, recent studies have
shown that endocannabinoids not only inhibit the JNK
activation induced by inflammatory stimuli [59,60], but
also induce expression of MKP-1 [61,62]. We found that
b o t h2 - A Ga n dE T Y As u p p r e s s e dI F N - g-induced JNK
phosphorylation and CCL2/MCP-1 expression, and inhib-
ited MKP-1 synthesis in rat astrocytes. Further, we deter-
mined that the mechanism of 2-AG action was CB1
receptor-dependent but PPAR-a-independent, and that
ETYA action did not require either receptor. This means
that the signaling mechanisms regulating the level of
MKP-1 expression differ in nature (Additional file 6: Fig-
ure S6). This results suggest another important point that
the eicosanoid, ETYA, and the cannabinoid derivative, 2-
AG, which evidence suggests share some structural and
functional similarities [58], regulate MKP-1 in brain glial
cells through different mechanisms. Thus, although both
agents increased MKP-1 expression, the underlying
mechanisms were quite different, with ETYA increasing
MKP-1 mRNA levels post-transcriptionally, and 2-AG
likely regulating MKP-1 expression at the transcriptional
level (Figure S6G, and data not shown). Although the
molecular targets of these agents upstream of MKP-1 are
not yet known, it is important to note that these structu-
rally similar compounds actively regulate MKP-1 levels
through transcriptional and post-transcriptional mechan-
isms in a target- and cell-specific manner. In this context,
identifying the specific underlying mechanism could pro-
vide a novel therapeutic target for anti-inflammatory
drugs. Importantly, the development of such drugs that
target different mechanisms could not only reduce side
effects on other organs, but could also eliminate undesir-
able induction of receptor-dependent target genes.
Conclusions
In this study, we demonstrated a novel anti-inflammatory
mechanism of ETYA, a PPAR-a ligand, by increasing
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Figure 6 A model showing the anti-inflammatory mechanism
of ETYA in IFN-g-stimulated glial cell. IFN-g induces JNK/Jun
phosphorylation and increases CCL2/MCP-1 gene expression. ETYA,
but not fibrates, increases MKP-1 mRNA stability by inducing HuR
cytoplasmic shuttling, and thereby suppresses IFN-g-induced JNK
signaling and CCL2/MCP-1 expression.
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Page 10 of 13HuR-mediated-MKP-1 mRNA stability that leads to the
specific suppression of CCL2/MCP-1 during inflammatory
processes. ETYA induced HuR-MKP-1 nucleocytoplasmic
translocation, which subsequently, served to protect MKP-
1 mRNA from the mRNA degradation machinery. These
findings establish a novel mechanism in which ETYA
increases MKP-1 expression through HuR at the post-
transcriptional level in a receptor-independent manner.
Additional material
Additional file 1: Figure S1. Dose-related effect of PPAR-a activators on
inflammatory mediators expression in IFN-g-stimulated astrocytes. Primary
astrocytes were stimulated with IFN-g for 2 h in the presence of the
indicated concentrations of individual PPAR-a activators. Then, MCP-1
and TNF-a mRNA levels were determined using RT-PCR.
Additional file 2: Figure S2. ETYA increases recruitment of Mbd3/
HDAC1 to the AP-1 site of MCP-1 through JNK unpohosphoryation.
Astrocytes were treated with ETYA or SP600125, a chemical inhibitor of
JNK phosphorylation, and prepared for ChIP assays. “Input” indicates
control PCR and shows the amount of CCL2/MCP-1 promoter DNA
present in each sample before ChIP.
Additional file 3: Figure S3. WY14643 and ETYA induce equivalent
reductions in MCP-1 transcript levels and protein release in IFN-g-
stimulated peritoneal macrophages. (A and B) Peritoneal macrophages
were stimulated with IFN-g for 2 or 12 h in the presence of the indicated
levels of individual PPAR-a activators. Then, MCP-1 and MKP-1 mRNA
levels (A) and MCP-1 protein secretion into media (B) were determined
using RT-PCR and ELISA, respectively. ELISA data are presented as means
± SEMs of three independent experiments (*p < 0.01 versus IFN-g group).
Additional file 4: Figure S4. ETYA promotes HuR translocation to stress
granules (SGs), not processing bodies (PBs). (A and B) Confocal
microscopic images of astrocytes immunostained with HuR, TIA1 (SG
marker) (A), or DCP1a (PB marker) (B) under the indicated conditions.
Insets are magnified images of the corresponding boxed regions. Scale
bars, 20 μm. Arrows indicate co-localization of HuR and TIA1.
Additional file 5: Figure S5. ETYA increases HuR serine phosphorylation.
Astrocytes were stimulated with IFN-g in the presence or absence of
ETYA, and nuclear extracts (NE) and cytosolic extracts (CE) were
immunoprecipitated with an anti-phospho-serine antibody.
Phosphorylation of HuR in immunoprecipitates was measured by
Western blot analysis using an anti-HuR antibody.
Additional file 6: Figure S6. 2-AG also suppresses CCL2/MCP-1
expression by inducing MKP-1 expression. (A and B) Astrocytes were
stimulated with IFN-g for 2 h in the absence or presence of the indicated
dose of 2-AG. MKP-1 protein expression and JNK phosphorylation were
analyzed by Western blotting (A), and MKP-1 and CCL2/MCP-1 transcript
levels were examined by qRT-PCR (B). (C-F) Cells were transfected with
siRNA duplexes specific for PPAR-a (C and D) or CB1 (E and F), and 48 h
later were stimulated with IFN-g for 2 h in the presence of 2-AG or ETYA.
MKP-1 protein level and JNK phosphorylation were analyzed by Western
blotting (C and E), and MKP-1 and CCL2/MCP-1 transcript levels were
examined by qRT-PCR (D and F). (G) Astrocytes were treated with Act D
for the indicated periods in the presence of 2-AG, after which MKP-1
mRNA levels were determined by qRT-PCR.
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